display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)mHCC - 1st line (L1)mHCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab IMbrave050 IMbrave-150
atezolizumab plus cabozantinib COSMIC-312
camrelizumab based treatment CARES-310
durvalumab based treatment
durvalumab plus bevacizumab EMERALD-1
nivolumab based treatment
nivolumab alone CheckMate 459
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-240 KEYNOTE-394
pembrolizumab plus lenvatinib LEAP 002
sintilimab based treatment
sintilimab Wang ORIENT-32
Tislelizumab RATIONALE 301
Immune checkpoint association
durvalumab plus tremelimumab HIMALAYA
nivolumab plus ipilimumab NCI-2018-01106
nivolumab plus ipilimumab plus SoC CheckMate 9DW

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons